## 10/579825 AP9 Rec'd PCF/PTO 17 MAY 2006

## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. PCT/EP2004/012076 International Filing Date 26 October 2004 (26.10.2004) 19 November 2003 (19.11.2003) Priority Date(s) Claimed Applicant(s) (DO/EO/US) FINSINGER, Dirk et al. Title: PYRROLE DERIVATIVES INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees  $\boxtimes$ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d);  $\boxtimes$ within three months of the actual filing date of the national phase of a PCT application; OR before the mailing of a first substantive office action (including after filing of an RCE).

> a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods

specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

,	•	is acco	impanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR			
			a check covering the fee of \$180.00 under 37 C.F.R. $\S~1.17(p).$			
			R. $\S$ 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:			
		a final	action under 37 C.F.R. § 1.113;			
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);			
		OR a	notice of allowance under 37 C.F.R. § 1.311;			
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:			
		the sta \$180.0	tement as specified in 37 C.F.R. $\S$ 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. $\S$ 1.17(p).			
State	ments U	Inder 37	C.F.R. 1.97(e)			
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cite	d Materi	ials				
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).				
	$\boxtimes$		es of materials listed but not attached were cited in an international search t dated $\underline{\text{January } 20,2005}$ .			
		Not r	equired by 37 CFR § 1.98.			
		Copie	es of the materials listed are attached (except for the foregoing).			

Non-Eng	rlish Language References
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date</li> <li>D = cited in the application</li> <li>L = cited for another reason</li> </ul>
	& = publication of member of same patent family
L	Translation of other relevant information on foreign search report  In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwachnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.
Other In	formation
_	of Fees Due (If Any): A check for \$ covering the fee identified above is attached.
F	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.

## IAP9 REC'OPENTIO 17 MAY 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3165

Date: May 17, 2006

AJZ:aap

K:\Merck\3000 - 3999\3165\Information Disclosure Statement.doc

of

Sheet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons		on of information unless it contains a valid OMB control n				
Substitute for form 1449A/PTO		Application Number 11/2 SMM 17/11/10 17 NAY 2006				
,	Application Number	Unassigned 101110 1	1 MAI	<b>4000</b>		
INFORMATION DISCLOSURE	Filing Date	May 17, 2006				
STATEMENT BY APPLICANT	First Named Inventor	FINSINGER, Dirk et al.				
	Group Art Unit	Unassigned				
(use as many sheets as necessary)	Examiner Name	Unassigned				

Attorney Docket Number

MERCK-3165

U.S. PATENT DOCUMENTS							
Cite No.1	U.S. Patent Docume	nt Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY			
1	2004138269		SUN CONNIE LE ET AL.	July 15, 2004			
2	2004254186			December 16, 2004			
			-				
	1	Cite No.1 Number 1 2004138269	U.S. Patent Document   Kind Code <sup>2</sup>	U.S. Patent Document			

				FOR	EIGN PATENT DOCUMEN			
Examiner		Foreign Patent Document Kind Code <sup>5</sup>			Name of Patentee or Applicant of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	Cite No.1	Office <sup>3</sup>	Number*	(if known)	Cited Document	MM-DD-YYYY	Figures Appear	
/K.B./	3	wo	03022833		NAYLOR ANTOINETTE	March 20, 2003		Equv to cite 2
				<b>-</b>				
		-		+			1	

Examiner Signature	/Kristin Bianchi/	Date Considered	12/16/2008	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that is sued the document, by the two-letter code (WIPO Standard ST.3.) For Japanese patent documents, the indication of the year of the reign of the Temporer must precede the serial number of the patent document. <sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1 of possible. <sup>3</sup> Applicant Is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Otliner, U.S. Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner of Patients, P.O. Box 1450, Alexandria, VA 22313-1450.